Table 3.
Recommendations for NS5A RAS Testing by Regimen and Clinical Characteristics (Treatment Experience and Cirrhosis)
| HCV Genotype 1a | HCV Genotype 1b | HCV Genotype 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TN | TEa | TN | TEa | TN | TEa | |||||||
| HCV Regimen | NC | C | NC | C | NC | C | NC | C | NC | C | NC | C |
| Elbasvir/grazoprevirb | + | + | + | + | − | − | − | − | NA | NA | NA | NA |
| Ledipasvir/sofosbuvirb | − | +/− | +/− | +/− | − | − | − | − | NA | NA | NA | NA |
| Paritaprevir/ritonavir/ombitasvirb plus dasabuvir | − | − | − | − | − | − | − | − | NA | NA | NA | NA |
| Sofosbuvir plus daclatasvir | − | − | − | − | − | − | − | − | − | + | + | − |
| Sofosbuvir/velpatasvirb | − | − | − | − | − | − | − | − | − | + | + | − |
Abbreviations: +, resistance testing recommended; +/−, resistance testing may be considered; resistance testing not recommended; C, cirrhosis; HCV, hepatitis C virus; NA, not applicable; NC, no cirrhosis; NS5A, nonstructural protein 5A; RAS, resistance-associated substitution;
a
With peginterferon alfa−based regimen; excludes prior NS5A-containing regimens.
b
Slash indicates a coformulation.